Literature DB >> 861066

Association of renal papillary necrosis and ankylosing spondylitis.

S H Lourie, S J Denman, E T Schroeder.   

Abstract

Three patients with ankylosing spondylitis developed renal papillary necrosis. All had received prostaglandin synthetase inhibitors including phenylbutazone, indomethacin, or ibuprofen. One patient had sickle trait. These drugs are not commonly associated with papillary necrosis in man, but may adversely effect renal medullary blood flow. An underlying renal vascular abnormality related to ankylosing spondylitis is also considered. Patients with ankylosing spondylitis who are taking prostaglandin synthetase inhibitors should be routinely screened for hematuria.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 861066     DOI: 10.1002/art.1780200403

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  5 in total

1.  A prospective study of renal disease in patients with early rheumatoid arthritis.

Authors:  Y Koseki; C Terai; M Moriguchi; M Uesato; N Kamatani
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

Review 2.  Analgesic nephropathy: a reassessment of the role of phenacetin and other analgesics.

Authors:  L F Prescott
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

Review 3.  Glomerular, tubular and interstitial nephritis associated with non-steroidal antiinflammatory drugs. Evidence of a common mechanism.

Authors:  U Ravnskov
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

4.  Increased incidence of recurrent hematuria in ankylosing spondylitis: a possible association with IgA nephropathy.

Authors:  B A Wall; C A Agudelo; E J Pisko
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

5.  Relation of microscopic haematuria in ankylosing spondylitis to circulating IgA containing immune complexes.

Authors:  A J Peeters; A W van den Wall Bake; A D van Dalsen; M L Westedt
Journal:  Ann Rheum Dis       Date:  1988-08       Impact factor: 19.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.